Browse News
Filter News
Found 213 articles
-
Myovant Sciences Announces Corporate Updates and Financial Results for First Fiscal Quarter 2022
7/27/2022
Myovant Sciences announced financial results for the first quarter of fiscal year 2022 and provided other corporate updates.
-
The Impact of Urinary Incontinence Related to Overactive Bladder on Long-Term Care Residents and Facilities in the U.S. Highlighted in New Survey
7/13/2022
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the peer-reviewed journal publication of the findings from a survey of Directors of Nursing (DONs) in U.S. long-term care settings.
-
Urovant Sciences® Named One of 2022 “Best Places to Work” in Orange County
7/7/2022
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., has been named for the 2nd year in a row as one of the Best Places to Work by the Orange County Business Journal.
-
Urovant Sciences and Pierre Fabre Médicament Enter into Exclusive License Agreement to Commercialize Vibegron for the Treatment of Overactive Bladder in the European Economic Area, UK, and Switzerland
7/5/2022
Urovant Sciences and Pierre Fabre Médicament today announced they have entered into an exclusive license agreement for Pierre Fabre to register and commercialize vibegron for the treatment of Overactive Bladder (OAB).
-
Enzyvant Receives 2022 Rare Impact Industry Innovation Award from the National Organization for Rare Disorders (NORD) for Novel, Tissue-Based Therapy to Treat Ultra-Rare, Life-Threatening Pediatric Condition
6/27/2022
Enzyvant announced it is among the National Organization for Rare Disorders 2022 Industry Innovation Awards recipients for the development and U.S. Food and Drug Administration approval of RETHYMIC®, a one-time regenerative tissue-based therapy for pediatric congenital athymia.
-
GlobalData Plc: FDA Approved 122 New Drug Applications and Biologics License Applications in 2021
5/19/2022
In 2021, the FDA approved 122 New Drug Applications (NDAs) and Biologics License Applications (BLAs), including new molecular entities (NMEs), biologics approved as BLAs through the Center for Biologics Evaluation and Research (CBER), and new formulations of older drugs.
-
Spirovant Launches State-of-the-Art Laboratory and Headquarters
5/16/2022
Spirovant Sciences, a gene therapy company developing treatments for respiratory diseases, including cystic fibrosis, announced the launch of its new state-of-the-art research laboratory and corporate headquarters in Philadelphia.
-
Urovant Sciences® Presents New Data from EMPOWUR Study, Advancing Knowledge of the Treatment of Overactive Bladder at the 2022 American Urological Association Meeting
5/15/2022
Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., announced new analyses from the Phase 3 EMPOWUR Extension Study of GEMTESA, presented Sunday at the 2022 annual meeting of the American Urological Association.
-
Urovant Sciences® Presents Interim Data from Phase 2a Study of Investigational Novel Gene Therapy, URO-902, Supporting Safety, Tolerability, and Efficacy Endpoints at 2022 American Urological Association Meeting
5/13/2022
Urovant Sciences, a wholly owned subsidiary of Sumitovant Biopharma Ltd., announced that positive interim results from a Phase 2a trial of its investigational novel gene therapy, URO-902, were presented Friday at the 2022 annual meeting of the American Urological Association (AUA2022).
-
Myovant Sciences Announces Corporate Updates and Financial Results for Fourth Fiscal Quarter and Fiscal Year Ended March 31, 2022
5/10/2022
Myovant Sciences announced financial results for the fourth fiscal quarter and fiscal year ended March 31, 2022 and provided other corporate updates.
-
Biogen is bolstering its multiple sclerosis (MS) pipeline through a licensing agreement with Maine-based MedRhythms for its investigational digital therapeutic, MR-004.
-
ALTAVANT SCIENCES PRESENTS DATA SHOWING POTENTIAL FOR COMBINATION OF RODATRISTAT ETHYL AND AMBRISENTAN IN MODEL OF PULMONARY ARTERIAL HYPERTENSION
5/6/2022
Altavant Sciences, announced today that the company is presenting results from a preclinical study comparing rodatristat ethyl as a monotherapy and in combination with the type A endothelin receptor antagonist, ambrisentan, in an animal model of pulmonary arterial hypertension (PAH).
-
Biogen announced the leadership change in its quarterly financial report. Michel Vounatsos plans to depart the company when a new CEO is found.
-
ALTAVANT SCIENCES PRESENTED DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530
5/2/2022
Altavant Sciences announced today that the company made an oral presentation of preclinical results supporting the development of ALTA-2530 for the treatment of bronchiolitis obliterans syndrome.
-
ALTAVANT SCIENCES TO PRESENT DATA AT ISHLT SHOWING POTENCY AND DISTRIBUTION OF BRONCHIOLITIS OBLITERANS CANDIDATE, ALTA-2530
4/25/2022
Altavant Sciences announced today that the company will make an oral presentation on preclinical results supporting the development of ALTA-2530 for the treatment of bronchiolitis obliterans.
-
Enzyvant Announces Plans to Expand Regenerative Medicine Manufacturing Capabilities
4/21/2022
Enzyvant announced plans to develop a Good Manufacturing Practice -compliant regenerative medicine manufacturing facility in Morrisville, NC, part of the Research Triangle Park area.
-
Urovant Sciences Announces Publication of EMPOWUR Trial Subgroup Analysis Showing Similar Efficacy for GEMTESA® in Dry and Wet Overactive Bladder Populations
4/19/2022
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new, post-hoc analysis of data from the Phase 3 EMPOWUR trial of GEMTESA (vibegron) 75 mg in the International Journal of Clinical Practice.
-
Urovant Sciences to Present Interim Data from Phase 2a Study of Potential Novel Gene Therapy, URO-902, and New Analyses of Data from Phase 3 EMPOWUR Extension Trial of GEMTESA® (vibegron) 75 mg at 2022 AUA Annual Meeting
4/13/2022
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., announced that data from a Phase 2a trial of the investigational, novel gene therapy, URO-902, will feature as a late-breaker at the 2022 annual meeting of the American Urological Association, May 13-16, in New Orleans, Louisiana.
-
Urovant Sciences Announces Appointment of Sef Kurstjens as Executive Vice President and Chief Medical Officer
4/4/2022
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced Sef Kurstjens, M.D., PhD., has been appointed Executive Vice President and Chief Medical Officer (CMO).
-
Urovant Sciences Announces Publication of New Review of Efficacy and Safety Data for GEMTESA® (vibegron) 75 mg in Overactive Bladder Patients in the Journal Therapeutics and Clinical Risk Management
3/22/2022
Urovant Sciences, a wholly-owned subsidiary of Sumitovant Biopharma Ltd., today announced the publication of a new review of data on GEMTESA (vibegron) 75 mg in the peer-reviewed journal, Therapeutics and Clinical Risk Management (https://bit.ly/Vibegron).